Understanding 2-FDCK: A Research Chemical Overview

2-Fluorodeschloroketamine (2-FDCK) is a synthetic arylcyclohexylamine compound that has emerged as a notable new psychoactive substance (NPS) in research chemical literature. At 4mmcchems, we provide high-quality 2-FDCK crystals specifically for laboratory research applications.

Chemical Profile

2-FDCK is a fluorinated analog of ketamine, structurally modified by replacing the chlorine atom with a fluorine group at the ortho position of the phenyl ring. Its IUPAC name is 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one, with a molecular formula of C₁₃H₁₆FNO and a molecular weight of 221.27 g/mol. The compound contains a chiral center, allowing for two enantiomers: (R)-2-FDCK and (S)-2-FDCK.

The substitution of chlorine with fluorine significantly alters the compound’s metabolic profile. The carbon-fluorine bond (approximately 485 kJ/mol) is considerably stronger than the carbon-chlorine bond (approximately 327 kJ/mol), making 2-FDCK more resistant to direct halogen cleavage by cytochrome P450 enzymes. Research indicates that 2-FDCK exhibits a slower internal clearance rate compared to ketamine.

Research Context

2-FDCK functions as an NMDA receptor antagonist, similar to ketamine and other arylcyclohexylamines. Preclinical studies demonstrate that 2-FDCK produces rewarding and reinforcing effects in animal models. Conditioned place preference (CPP) studies in mice have shown that 2-FDCK induces CPP at a minimum dose of 3 mg/kg, while self-administration studies in rats indicate readily induced responding at 0.5 mg/kg/infusion.

Pharmacokinetic research in rodent models has identified nor-2-FDCK as the primary phase I metabolite, with elimination half-lives of 0.20 hours (low-dose) and 1.07 hours (high-dose) for the parent compound. The metabolite nor-2-FDCK remains detectable in blood at 12 hours post-administration, suggesting its utility as a biomarker for forensic identification.

Recent investigations have also explored the neurodevelopmental implications of 2-FDCK exposure. Studies using human cerebral organoids indicate that 2-FDCK can disrupt mitochondrial oxidative phosphorylation, potentially increasing vulnerability to neurological issues during developmental periods.

Quality Standards at 4mmcchems

Every batch of 2-FDCK crystals undergoes comprehensive analytical verification. Our products are accompanied by certificates of analysis documenting purity levels, chemical composition, and relevant spectroscopic data. We maintain complete batch records for all research chemicals, with HPLC data and mass spectrometry results available for each lot.

Documentation and Compliance

4mmcchems provides certificates of analysis and technical documentation to support research requirements. Our quality assurance framework includes standardized testing protocols and multi-stage verification processes.

Important Notice

2-FDCK has been identified in 22 EU member states, with two confirmed deaths and 11 acute poisonings reported across three member states. The World Health Organization has recommended its inclusion in Schedule II of the Convention on Psychotropic Substances of 1971. The DEA has moved to temporarily classify 2-FDCK as a Schedule I controlled substance in the United States. Researchers must verify their legal authority to handle such compounds and comply with all applicable regulations in their location. Our products are supplied strictly for laboratory research purposes and are not intended for human consumption.